"The acquisition of FGL enables NEB to combine our expertise in enzyme manufacturing and assay development with their expertise in lyophilization, providing a complete solution for our customers," states Jim Ellard, CEO of New England Biolabs. "It also further solidifies our ability to service customers in the molecular diagnostics space."
Martin Lee, Co-founder CEO of Fluorogenics, Ltd., states, "We are delighted to become part of an organization with which we share ideals, innovation and technical excellence, a passion to make a difference through the delivery of scientific solutions that create value for our customers, and reduce the burden on our planet."
FGL's operations will continue without disruption to its existing customers. NEB will be making further investments to strengthen their operations. Further, NEB will be incorporating FGL's capabilities into its existing OEM and Customized Solutions business, expanding the services that it offers.
Many scientists know NEB as a trusted reagent provider to the life science community. What many do not know is that it also offers a portfolio of products, including PCR/qPCR, LAMP and NGS reagents, that serve as critical components for a wide array of diagnostic products and services. Extensive molecular biology and enzymology experience provides NEB with the unique ability to help customers solve the challenges inherent in diagnostics assay development and ultimately in scale-up and commercialization. This capability now also includes lyophilzation.
About New England Biolabs
Established in the mid 1970's, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including molecular diagnostics development. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and eight subsidiaries located in Australia, Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs, visit www.neb.com.